Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses
Abstract The 2022 KDIGO guideline for diabetes management in patients with chronic kidney disease (CKD) had endorsed the use of GLP-1 receptor agonists (GLP-1RAs) for patients with CKD and type 2 diabetes who did not achieve optimal glycemic target with maximally tolerated Rangehood Filter Cleaner metformin and sodium-glucose co-transporter-2 (SGLT